Foghorn Therapeutics
FHTX
62 hedge funds and large institutions have $226M invested in Foghorn Therapeutics in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 6 closing their positions.
65,000% more call options, than puts
Call options by funds: $651K | Put options by funds: $1K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
3% more funds holding
Funds holding: 60 → 62 (+2)
6% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 17
0.18% less ownership
Funds ownership: 63.36% → 63.18% (-0.18%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less capital invested
Capital invested by funds: $357M → $226M (-$132M)
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$2.39M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$681K |
| 3 |
BlackRock
New York
|
-$341K |
| 4 |
DTL
Dynamic Technology Lab
Singapore
|
-$279K |
| 5 |
BC
Birchview Capital
Burlington,
Vermont
|
-$257K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
51
Ameritas Investment Partners
Lincoln,
Nebraska
| $13K | – | – | – |
|
|
WT
52
Washington Trust
Westerly,
Rhode Island
| $13K | – | – | – |
|
|
PHK
53
Point72 Hong Kong
Hong Kong
| $10K | +$12.7K | +989 | +487% |
|
54
Barclays
London,
United Kingdom
| $7K | -$2.01K | -156 | -15% |
|
|
CAL
55
Capital Analysts LLC
Fort Washington,
Pennsylvania
| $5K | – | – | – |
|
56
Citigroup
New York
| $3K | -$12.8K | -994 | -77% |
|
57
Wells Fargo
San Francisco,
California
| $3K | -$2.51K | -195 | -35% |
|
58
Osaic Holdings
Scottsdale,
Arizona
| $3K | – | – | – |
|
|
CS
59
Credit Suisse
Zurich,
Switzerland
| $1K | +$1.18K | +92 | +460% |
|
60
Group One Trading
Chicago,
Illinois
| $1K | +$1.29K | +100 | New |
|
|
DTL
61
Dynamic Technology Lab
Singapore
| – | -$279K | -20,551 | Closed |
|
|
XT
62
XTX Topco
George Town,
Cayman Islands
| – | -$156K | -11,436 | Closed |
|
|
CSS
63
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$3K | -209 | Closed |
|
|
LC
64
Lindbrook Capital
Calabasas,
California
| – | -$1.38K | -107 | -82% |
|
|
S
65
SignatureFD
Atlanta,
Georgia
| – | -$1K | -45 | Closed |
|
FHTX Hedge Fund Activity: Q3 2022 in Review
62 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q3 2022, worth a combined $226M — down 37% from $357M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new FHTX positions and 6 closed out — a net gain of 2 holders — while 18 added to existing stakes and 17 trimmed.
The largest buyer was Rockwood Wealth Management, opening a new position worth an estimated $1.6M. The largest seller was Morgan Stanley, cutting an estimated $2.39M.
- 62 institutional investors held Foghorn Therapeutics (FHTX) as of Q3 2022, up from 60 in Q2 2022.
- Funds reported $226M of Foghorn Therapeutics stock for Q3 2022, down 37% quarter-over-quarter.
- 8 funds opened new Foghorn Therapeutics positions in Q3 2022 and 6 closed out, a net change of +2 holders.
- The largest Foghorn Therapeutics buyer in Q3 2022 was Rockwood Wealth Management, an estimated $1.6M added.
- The largest Foghorn Therapeutics seller in Q3 2022 was Morgan Stanley, an estimated $2.39M sold.
Based on aggregated 13F filings for Q3 2022.